BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 33020649)

  • 21. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
    Ettrich TJ; Schwerdel D; Dolnik A; Beuter F; Blätte TJ; Schmidt SA; Stanescu-Siegmund N; Steinacker J; Marienfeld R; Kleger A; Bullinger L; Seufferlein T; Berger AW
    Sci Rep; 2019 Sep; 9(1):13261. PubMed ID: 31519967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
    Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
    Bando H; Nakamura Y; Taniguchi H; Shiozawa M; Yasui H; Esaki T; Kagawa Y; Denda T; Satoh T; Yamazaki K; Sunakawa Y; Kato T; Goto M; Yuki S; Nishina T; Oki E; Shinozaki E; Matsuhashi N; Takahashi N; Tsuji A; Ohtsubo K; Wakabayashi M; Ikeno T; Hata M; Odegaard JI; Yoshino T
    JCO Precis Oncol; 2022 Apr; 6():e2100535. PubMed ID: 35544728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
    Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
    Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
    Merker JD; Oxnard GR; Compton C; Diehn M; Hurley P; Lazar AJ; Lindeman N; Lockwood CM; Rai AJ; Schilsky RL; Tsimberidou AM; Vasalos P; Billman BL; Oliver TK; Bruinooge SS; Hayes DF; Turner NC
    J Clin Oncol; 2018 Jun; 36(16):1631-1641. PubMed ID: 29504847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
    Bratman SV; Newman AM; Alizadeh AA; Diehn M
    Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
    Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
    Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.